Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Average relative dose intensity and the impact on design of clinical trials.

× No keyword cloud information.

35 in total

Review 1. Drug resistance in oncology: from concepts to applications.

Authors: J L Cazin; P Gosselin; P Cappelaere; J Robert; A Demaille
Journal: J Cancer Res Clin Oncol Date: 1992 Impact factor: 4.553

Review 2. The concept of dose intensification in the treatment of neoplastic disease.

Authors: U B Wandl; N Niederle
Journal: Infection Date: 1992 Impact factor: 3.553

Review 3. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs.

Authors: W E Evans; M V Relling
Journal: Clin Pharmacokinet Date: 1989-06 Impact factor: 6.447

4. A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002.

Authors: Tomohiro Kinoshita; Tomomitsu Hotta; Kensei Tobinai; Tohru Kobayashi; Naoki Ishizuka; Masao Tomonaga; Toshiaki Sai; Youichiro Ohno; Masaharu Kasai; Michinori Ogura; Chikara Mikuni; Hironobu Toki; Masayuki Sano; Yasufumi Masaki; Tomoko Ohtsu; Yoshihiro Matsuno; Takeaki Takenaka; Shigeru Shirakawa; Masanori Shimoyama
Journal: Int J Hematol Date: 2004-11 Impact factor: 2.490

5. A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.

Authors: T Langenbuch; K Mross; W Jonat; D K Hossfeld
Journal: Cancer Chemother Pharmacol Date: 1990 Impact factor: 3.333

6. Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.

Authors: S D Harrison; J Plowman; D J Dykes; W R Waud; D P Griswold
Journal: Cancer Chemother Pharmacol Date: 1990 Impact factor: 3.333

Review 7. Modeling Tumor Clonal Evolution for Drug Combinations Design.

Authors: Boyang Zhao; Michael T Hemann; Douglas A Lauffenburger
Journal: Trends Cancer Date: 2016-03

8. Phase I study of high-dose cisplatin, ifosfamide, and etoposide.

Authors: E A Perez; P C Sowray; S L Gardner; D R Gandara
Journal: Cancer Chemother Pharmacol Date: 1994 Impact factor: 3.333

9. Attempted dose intensified cyclophosphamide, etoposide, and granulocyte colony-stimulating factor for treatment of malignant astrocytoma.

Authors: H B Newton; C L Newton
Journal: J Neurooncol Date: 1995 Impact factor: 4.130

10. A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.

Authors: L B Grochow; D A Noe; D S Ettinger; R C Donehower
Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333